AbbVie Inc. (NYSE:ABBV) will begin trading ex-dividend on July 14, 2020. The quarterly dividend payment of $ 1.18 per share is scheduled to be paid on August 14, 2020. To secure the dividend payout, investors must buy the stock prior to the ex-dividend date, latest at the end of the trading session on July 14, 2020.
Dividends History
wpDataTable with provided ID not found!Click Here For More Historical Dividends Of AbbVie Inc.
Recent Earnings Announcement
AbbVie Inc. came out with income for the first quarter of $ 2.42 per share, from the revenue of $ 8,619.00 million. The quarterly earnings enlarged 13.08 percent while revenues improved 10.10 percent compared with the same quarter last year.
Street analysts expected AbbVie Inc. to report income of $ 2.25 per share on revenue of $ 8325.45 million for the first quarter. The bottom line results beat street analysts by $ 0.17 or 7.56 percent, at the same time, top line results topped analysts by $ 293.55 million or 3.53 percent.
Stock Performance
According to the previous trading day, closing price of ABBV was $ 97.86, representing a 56.45 % increase from the 52 week low of $ 62.55 and a 2.81 % decrease over the 52 week high of $ 100.69.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”ABBV” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
The company has a market capital of $ 172.46 billion and is part of the Healthcare sector and Drug Manufacturers – Major industry.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçets diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenströms macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
